Biotest AG
Biotest AG (BTTAY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bttay · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Biotest AG (BTTAY) measures how much investors pay for each dollar of the company's trailing earnings. BTTAY's current PE ratio of N/A is calculated by dividing its stock price of $24.23 by its TTM earnings per share of -$0.64.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 11 fiscal years · Front-end computedMinQ1 · 25%41.2x
MedianQ3 · 75%82.7x
Max
At N/A, BTTAY's current P/E is lower than in 0% of its annual fiscal year readings over the past 11 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biotest AGYou BTTAY | $943M | N/A | — | -$0.64 |
 Opthea Limited CKDXF | $602M | N/A | — | -$0.13 |
 Claritas Pharmaceuticals, Inc. CLAZF | $0M | 0.00x | -99.9% | $0.16 |
 China Shineway Pharmaceutical Group Limited CSWYF | $816M | 5.56x | +99.9% | $1.26 |
 EBR Systems, Inc. EBRCZ | $262M | N/A | — | -$0.12 |
 Inventiva S.A. IVEVF | $556M | N/A | — | -$1.90 |
 Kindstar Globalgene Technology, Inc. KDGTF | $675M | N/A | — | — |
Industry Average 2 peers with valid PE | — | 2.78x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 66.05x | $0.35 | +382.7% | |
2023-12-31 FY2023 | 13.68x | $1.60 | — | |
2022-12-31 FY2022 | — | $-0.40 | — | |
2021-12-31 FY2021 | — | $-0.80 | — | |
2020-12-31 FY2020 | — | $-0.40 | — | |
2019-12-31 FY2019 | — | $-0.06 | — | |
2018-12-31 FY2018 | 9.22x | $2.30 | — | |
2017-12-31 FY2017 | — | $-0.04 | — | |
2016-12-31 FY2016 | — | $-0.58 | — | |
2015-12-31 FY2015 | — | $-1.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biotest AG (BTTAY) measures how much investors pay for each dollar of the company's trailing earnings. BTTAY's current PE ratio of N/A is calculated by dividing its stock price of $24.23 by its TTM earnings per share of -$0.64.
Frequently asked questions
BTTAY pe ratio · 6 questionsBTTAY's current PE ratio is N/A as of 2026-06-08, based on a stock price of $24.23 and TTM EPS of -$0.64. Data sourced from Financial Modeling Prep via BTTAY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08